Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : No-Carrier-Added Lutetium-177
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Isotopia
Deal Size : Not Applicable
Deal Type : Not Applicable
Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers
Details : 177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.
Brand Name : n.c.a 177 Lu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2022
Lead Product(s) : No-Carrier-Added Lutetium-177
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Isotopia
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Under the terms of the agreement, CPDC will develop and manufacture CellBion's drug product Lu-177-PSMA-D GUL, for Phase II clinical supply in South Korea with the goal of expanding into North America.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 25, 2022
LOOKING FOR A SUPPLIER?
Reset All
